AP Gets First Notified Body for Medical Device Manufacturing Facilities Inspection

CDSCO has notified KIHT Certification Services (KCS) inside AMTZ as state’s first regulatory body

Visakhapatnam: Andhra Pradesh is now home to its first-ever CDSCO notified auditing body for medical devices. In a significant move, the Central Drugs Standard Control Organisation (CDSCO) under Minister of Health and Family Welfare, Govt. of India has notified KIHT Certification Services (KCS) as the state’s first regulatory body authorised to inspect manufacturing facilities for Class A and Class B medical devices.

Among 14 such notified bodies nationwide, KCS is the only one operational in Andhra Pradesh and Telangana, marking a milestone in the region’s quality management capabilities. Founded in July 2017, Kalam Institute of Health Technology (KIHT) housed inside the AMTZ campus is a Government of India project supported by the Department of Biotechnology, at promoting and supporting innovations in medical technologies through research and development, industry promotion, policy-making and knowledge repository.

Founded in April 2022, KCS is accredited by the National Accreditation Board for Certification Bodies (NABCB) under ISO/IEC 17021 1:2015 and IAF MD 9:2023 standards. The organisation offers comprehensive services including ISO 13485 certification, quality systems audits, risk management training, and CE mark consultancy—making it a full-service hub for manufacturers seeking to meet global regulatory standards.

This approval brings immediate benefits to domestic manufacturers, particularly MSMEs, by eliminating the need for audits outside the state—resulting in significant time and cost savings. It also reinforces Andhra Pradesh’s MedTech credentials, supporting national campaigns like “Make in India” and “ACI manufacturing,” while making the region highly attractive for future investments. This significant milestone empowers KCS to conduct independent regulatory audits for medical device manufacturers in accordance with the Medical Devices Rules (MDR) 2017 for Class A (low risk) and Class B (moderate risk), the state underscores its reputation as a business-friendly hub, ready to meet rising global demand in healthcare.

Related Posts

Piramal, Ajinomoto team on ADC development and manufacturing

Piramal Pharma Solutions, a global contract development and manufacturing organization, and Ajinomoto Bio-Pharma Services announced a strategic collaboration to support development and manufacturing of antibody-drug conjugates (ADCs) using AJICAP technology…

Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

New Delhi: Aurobindo Pharma Ltd on Friday said it has received final approval from the US health regulator to manufacture and market its generic version of glycerol phenylbutyrate oral liquid…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Piramal, Ajinomoto team on ADC development and manufacturing

Piramal, Ajinomoto team on ADC development and manufacturing

Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

Cancer cure must not be hostage to Big Pharma

Cancer cure must not be hostage to Big Pharma

GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India